Your Health, We Care
Multiple studies have shown that Crizotinib exhibits significant efficacy in treating advanced NSCLC patients who are ALK positive or ROS1 positive.
Studies have shown that Crizotinib, as a neoadjuvant therapy for resectable locally advanced ALK fusion mutated NSCLC patients, can induce tumor downgrading and improve the success rate of surgical resection.
